Cefuroxime Sodium

CHEMBL2146124 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
446.4 g/mol
LogP
Phase
4

The sodium salt form of cefuroxime is used parenterally for moderate to severe bacterial infections and for surgical prophylaxis. It provides the second-generation cephalosporin spectrum of activity of the parent compound against gram-positive and gram-negative pathogens. Dose adjustment is required in patients with significant renal impairment.

Berat Molekul

446,4000 g/mol

TPSA

202,00 Ų

Area Terapeutik

Mekanisme Kerja

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@H]12)c1ccco1.[Na+]

InChI

InChI=1S/C16H16N4O8S.Na/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20;/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24);/q;+1/p-1/b19-9-;/t10-,14-;/m1./s1

Molecular Formula

C16H15N4NaO8S

HBD / HBA

2 / 10

Ikatan yang Dapat Dirotasi

8

Atom Berat

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

The sodium salt form of cefuroxime is used parenterally for moderate to severe bacterial infections and for surgical prophylaxis. It provides the second-generation cephalosporin spectrum of activity of the parent compound against gram-positive and gram-negative pathogens. Dose adjustment is required in patients with significant renal impairment.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefuroxime Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2146124. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23670318. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.